9 completed, 4 terminated, 1 withdrawn. 8 Phase 2, 4 Phase 3, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 4 | Terminated 3, Completed 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Not applicable | 1 | Terminated 1 |
Follow L-BLP25: new trials by email Literature Review of L-BLP25 trials Research Report on L-BLP25
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer Tecemotide, Placebo, Cyclophosphamide (CPA) - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | EMD Serono | 35 | 2014-03-01 | 2017-08-23 |
| Tecemotide (L-BLP25) in Rectal Cancer Tecemotide (L-BLP25), cyclophosphamide (CPA), Chemoradiotherapy - Rectal Cancer | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 124 | 2012-02-01 | 2017-01-13 |
| Common Safety Follow-up Trial of Tecemotide (L-BLP25) Tecemotide, No intervention - Non-Small Cell Lung Cancer, Multiple Myeloma | Not applicable | Terminated | Merck KGaA, Darmstadt, Germany | 27 | 2012-01-01 | 2016-10-06 |
| Tecemotide (L-BLP25) in Prostate Cancer Radiation therapy, Goserelin, Cyclophosphamide - Prostate Cancer | Phase 2 | Completed | EMD Serono | 28 | 2011-10-24 | 2018-03-09 |
| L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases L-BLP25, Placebo - Colon Carcinoma, Rectum Carcinoma | Phase 2 | Completed | Prof. Dr. Carl Schimanski | 122 | 2011-08-01 | 2018-02-13 |
| BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery bevacizumab, Tecemotide, carboplatin - Lung Cancer | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 70 | 2011-01-17 | 2023-07-07 |
| Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population Tecemotide, Single low dose cyclophosphamide, Placebo - Non-Small Cell Lung Cancer | Phase 3 | Terminated | Merck KGaA, Darmstadt, Germany | 285 | 2009-12-01 | 2016-10-26 |
| STRIDE - STimulating Immune Response In aDvanced brEast Cancer Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide - Breast Cancer | Phase 3 | Terminated | EMD Serono | 16 | 2009-09-01 | 2014-07-24 |
| Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 178 | 2008-12-01 | 2015-10-21 |
| Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide - Multiple Myeloma | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 34 | 2008-01-01 | 2016-02-22 |
| Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo - Non-small Cell Lung Cancer | Phase 3 | Completed | EMD Serono | 1513 | 2007-01-01 | 2015-11-20 |
| Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best standard of care (BSC) - Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 22 | 2005-04-01 | 2015-08-18 |
| Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer Biological: MUC1 peptide specific immunotherapy, Cyclophosphamide (CPA) - Non-small Cell Lung Cancer (NSCLC) Stage III | Phase 1 | Withdrawn | Merck KGaA, Darmstadt, Germany | 2001-01-01 | 2017-02-28 | |
| Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best Supportive Care (BSC) - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 171 | 2000-08-01 | 2015-11-18 |
Carcinoma, Non-Small-Cell Lung (9) · Lung Neoplasms (3) · Carcinoma (2) · Multiple Myeloma (2) · Rectal Neoplasms (2) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Colonic Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Neoplasms (1) · Recurrence (1)
Merck KGaA, Darmstadt, Germany (8) · EMD Serono (4) · ECOG-ACRIN Cancer Research Group (1) · Prof. Dr. Carl Schimanski (1)
Germany (8) · United States (5) · Austria (3) · South Korea (3) · Australia (2) · Belgium (2) · China (2) · Czechia (2) · Hong Kong (2) · Israel (2) · Netherlands (2) · Poland (2) · Russia (2) · Singapore (2) · Slovakia (2)
Barbara Guenther (1) · Carl Christoph Schimanski, Prof. Dr. (1) · Jyoti D. Patel (1) · Oscar Kashala, MD, PhD, DSc (1)
PMID 34870327, PMID 40443562, PMID 16170175, PMID 21071331, PMID 21744082, PMID 21982342, PMID 24331154, PMID 24976972, PMID 25483677, PMID 25722382, PMID 32923171
2008 (1), U10CA180794 (1)